<?xml version="1.0" encoding="UTF-8"?><abstracts-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:dn="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:ait="http://www.elsevier.com/xml/ani/ait" xmlns:ce="http://www.elsevier.com/xml/ani/common" xmlns:cto="http://www.elsevier.com/xml/cto/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/abstract/scopus_id/85084941418</prism:url><dc:identifier>SCOPUS_ID:85084941418</dc:identifier><eid>2-s2.0-85084941418</eid><pubmed-id>32400863</pubmed-id><prism:doi>10.1093/protein/gzaa009</prism:doi><dc:title>Improved ligand-binding- and signaling-competent human NK2R yields in yeast using a chimera with the rat NK2R C-terminus enable NK2R-G protein signaling platform</dc:title><prism:aggregationType>Journal</prism:aggregationType><srctype>j</srctype><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><citedby-count>3</citedby-count><prism:publicationName>Protein engineering, design &amp; selection : PEDS</prism:publicationName><dc:publisher>NLM (Medline)</dc:publisher><source-id>14257</source-id><prism:issn>17410134</prism:issn><prism:volume>32</prism:volume><prism:issueIdentifier>10</prism:issueIdentifier><prism:startingPage>459</prism:startingPage><prism:endingPage>469</prism:endingPage><prism:pageRange>459-469</prism:pageRange><prism:coverDate>2019-12-31</prism:coverDate><openaccess>0</openaccess><openaccessFlag>false</openaccessFlag><dc:creator><author seq="1" auid="57204284651"><ce:initials>A.R.</ce:initials><ce:indexed-name>Jain A.R.</ce:indexed-name><ce:surname>Jain</ce:surname><ce:given-name>Abhinav R.</ce:given-name><preferred-name><ce:initials>A.R.</ce:initials><ce:indexed-name>Jain A.R.</ce:indexed-name><ce:surname>Jain</ce:surname><ce:given-name>Abhinav R.</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/57204284651</author-url><affiliation id="60017672" href="https://api.elsevier.com/content/affiliation/affiliation_id/60017672"/></author></dc:creator><dc:description><abstract xmlns="" original="y" xml:lang="eng"><publishercopyright>Â© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</publishercopyright><ce:para>The tachykinin 2 receptor (NK2R) plays critical roles in gastrointestinal, respiratory and mental disorders and is a well-recognized target for therapeutic intervention. To date, therapeutics targeting NK2R have failed to meet regulatory agency approval due in large part to the limited characterization of the receptor-ligand interaction and downstream signaling. Herein, we report a protein engineering strategy to improve ligand-binding- and signaling-competent human NK2R that enables a yeast-based NK2R signaling platform by creating chimeras utilizing sequences from rat NK2R. We demonstrate that NK2R chimeras incorporating the rat NK2R C-terminus exhibited improved ligand-binding yields and downstream signaling in engineered yeast strains and mammalian cells, where observed yields were better than 4-fold over wild type. This work builds on our previous studies that suggest exchanging the C-termini of related and well-expressed family members may be a general protein engineering strategy to overcome limitations to ligand-binding and signaling-competent G protein-coupled receptor yields in yeast. We expect these efforts to result in NK2R drug candidates with better characterized signaling properties.</ce:para></abstract></dc:description><link href="https://api.elsevier.com/content/abstract/scopus_id/85084941418" rel="self"/><link href="https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&amp;scp=85084941418&amp;origin=inward" rel="scopus"/><link href="https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&amp;scp=85084941418&amp;origin=inward" rel="scopus-citedby"/></coredata><affiliation id="60027950" href="https://api.elsevier.com/content/affiliation/affiliation_id/60027950"><affilname>Carnegie Mellon University</affilname><affiliation-city>Pittsburgh</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation id="60023004" href="https://api.elsevier.com/content/affiliation/affiliation_id/60023004"><affilname>University of Delaware</affilname><affiliation-city>Newark</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation id="60017672" href="https://api.elsevier.com/content/affiliation/affiliation_id/60017672"><affilname>Tulane University</affilname><affiliation-city>New Orleans</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation id="60004219" href="https://api.elsevier.com/content/affiliation/affiliation_id/60004219"><affilname>AstraZeneca</affilname><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation id="60003269" href="https://api.elsevier.com/content/affiliation/affiliation_id/60003269"><affilname>Princeton University</affilname><affiliation-city>Princeton</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><authors><author seq="1" auid="57204284651"><ce:initials>A.R.</ce:initials><ce:indexed-name>Jain A.R.</ce:indexed-name><ce:surname>Jain</ce:surname><ce:given-name>Abhinav R.</ce:given-name><preferred-name><ce:initials>A.R.</ce:initials><ce:indexed-name>Jain A.R.</ce:indexed-name><ce:surname>Jain</ce:surname><ce:given-name>Abhinav R.</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/57204284651</author-url><affiliation id="60017672" href="https://api.elsevier.com/content/affiliation/affiliation_id/60017672"/></author><author seq="2" auid="35080118500"><ce:initials>Z.T.</ce:initials><ce:indexed-name>Britton Z.T.</ce:indexed-name><ce:surname>Britton</ce:surname><ce:given-name>Zachary T.</ce:given-name><preferred-name><ce:initials>Z.T.</ce:initials><ce:indexed-name>Britton Z.T.</ce:indexed-name><ce:surname>Britton</ce:surname><ce:given-name>Zachary T.</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/35080118500</author-url><affiliation id="60023004" href="https://api.elsevier.com/content/affiliation/affiliation_id/60023004"/><affiliation id="60004219" href="https://api.elsevier.com/content/affiliation/affiliation_id/60004219"/></author><author seq="3" auid="57194283533"><ce:initials>C.E.</ce:initials><ce:indexed-name>Markwalter C.E.</ce:indexed-name><ce:surname>Markwalter</ce:surname><ce:given-name>Chester E.</ce:given-name><preferred-name><ce:initials>C.E.</ce:initials><ce:indexed-name>Markwalter C.E.</ce:indexed-name><ce:surname>Markwalter</ce:surname><ce:given-name>Chester E.</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/57194283533</author-url><affiliation id="60023004" href="https://api.elsevier.com/content/affiliation/affiliation_id/60023004"/><affiliation id="60003269" href="https://api.elsevier.com/content/affiliation/affiliation_id/60003269"/></author><author seq="4" auid="7403387058"><ce:initials>A.S.</ce:initials><ce:indexed-name>Robinson A.S.</ce:indexed-name><ce:surname>Robinson</ce:surname><ce:given-name>Anne S.</ce:given-name><preferred-name><ce:initials>A.S.</ce:initials><ce:indexed-name>Robinson A.S.</ce:indexed-name><ce:surname>Robinson</ce:surname><ce:given-name>Anne S.</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/7403387058</author-url><affiliation id="60017672" href="https://api.elsevier.com/content/affiliation/affiliation_id/60017672"/><affiliation id="60023004" href="https://api.elsevier.com/content/affiliation/affiliation_id/60023004"/><affiliation id="60027950" href="https://api.elsevier.com/content/affiliation/affiliation_id/60027950"/></author></authors></abstracts-retrieval-response>